BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21094047)

  • 1. 2-Arylbenzoxazoles as CETP inhibitors: raising HDL-C in cynoCETP transgenic mice.
    Kallashi F; Kim D; Kowalchick J; Park YJ; Hunt JA; Ali A; Smith CJ; Hammond ML; Pivnichny JV; Tong X; Xu SS; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Peterson LB; Rosa R; Sparrow CP; Wright SD; Sinclair PJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):558-61. PubMed ID: 21094047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Arylbenzoxazoles as CETP inhibitors: Substitution of the benzoxazole moiety.
    Smith CJ; Ali A; Chen L; Hammond ML; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Sinclair PJ
    Bioorg Med Chem Lett; 2010 Jan; 20(1):346-9. PubMed ID: 19914065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-(4-carbonylphenyl)benzoxazole inhibitors of CETP: scaffold design and advancement in HDLc-raising efficacy.
    Sweis RF; Hunt JA; Kallashi F; Hammond ML; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Rosa R; Peterson L; Sparrow CP; Wright SD; Anderson MS; Sinclair PJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1890-5. PubMed ID: 21147531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Arylbenzoxazoles as novel cholesteryl ester transfer protein inhibitors: optimization via array synthesis.
    Harikrishnan LS; Kamau MG; Herpin TF; Morton GC; Liu Y; Cooper CB; Salvati ME; Qiao JX; Wang TC; Adam LP; Taylor DS; Chen AY; Yin X; Seethala R; Peterson TL; Nirschl DS; Miller AV; Weigelt CA; Appiah KK; O'Connell JC; Michael Lawrence R
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2640-4. PubMed ID: 18374566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Arylbenzoxazoles as CETP inhibitors: substitution and modification of the alpha-alkoxyamide moiety.
    Hunt JA; Gonzalez S; Kallashi F; Hammond ML; Pivnichny JV; Tong X; Xu SS; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Sinclair PJ
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1019-22. PubMed ID: 20036121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromanol derivatives--a novel class of CETP inhibitors.
    Vakalopoulos A; Schmeck C; Thutewohl M; Li V; Bischoff H; Lustig K; Weber O; Paulsen H; Elias H
    Bioorg Med Chem Lett; 2011 Jan; 21(1):488-91. PubMed ID: 21084191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.
    Smith CJ; Ali A; Hammond ML; Li H; Lu Z; Napolitano J; Taylor GE; Thompson CF; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Cumiskey AM; Latham M; Peterson LB; Rosa R; Pivnichny JV; Tong X; Xu SS; Sinclair PJ
    J Med Chem; 2011 Jul; 54(13):4880-95. PubMed ID: 21682257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.
    Hildebrand RB; Lammers B; Meurs I; Korporaal SJ; De Haan W; Zhao Y; Kruijt JK; Praticò D; Schimmel AW; Holleboom AG; Hoekstra M; Kuivenhoven JA; Van Berkel TJ; Rensen PC; Van Eck M
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1439-45. PubMed ID: 20431066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: attenuation of hERG binding and improved HDLc-raising efficacy.
    Sweis RF; Hunt JA; Sinclair PJ; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Rosa R; Peterson L; Sparrow CP; Anderson MS
    Bioorg Med Chem Lett; 2011 May; 21(9):2597-600. PubMed ID: 21398121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel tetrahydrochinoline derived CETP inhibitors.
    Schmeck C; Gielen-Haertwig H; Vakalopoulos A; Bischoff H; Li V; Wirtz G; Weber O
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1740-3. PubMed ID: 20137927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
    Berti JA; Amaral ME; Boschero AC; Nunes VS; Harada LM; Castilho LN; Oliveira HC
    Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
    Schaefer EJ; Asztalos BF
    Curr Opin Cardiol; 2007 Jul; 22(4):373-8. PubMed ID: 17556892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.
    Escribano A; Mateo AI; Martin de la Nava EM; Mayhugh DR; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel AG; Sweetana SA; Cannady EA; Mantlo NB
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3671-5. PubMed ID: 22543028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a novel class of biphenyl CETP inhibitors.
    Lu Z; Napolitano JB; Theberge A; Ali A; Hammond ML; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7469-72. PubMed ID: 21041082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice.
    Harder C; Lau P; Meng A; Whitman SC; McPherson R
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):858-64. PubMed ID: 17272756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.